LINC00261 Suppresses Cisplatin Resistance of Esophageal Squamous Cell Carcinoma Through miR-545-3p/MT1M Axis. 2021

Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

To improve the survival rate and cure rate of patients, it is necessary to find a new treatment scheme according to the molecular composition of (ESCC) in esophageal squamous cell carcinoma. Long non-coding RNAs (lncRNAs) regulate the progression of ESCC by various pathophysiological pathways. We explored the possible function of the lncRNA LINC00261 (LINC00261) on cisplatin (DDP) resistance of ESCC and its relative molecular mechanisms. In the study, we found that LINC00261 was downregulated in ESCC tissues, cell lines, and DDP-resistant ESCC patients. Besides, overexpression of LINC00261 not only inhibited cell proliferation, and DDP resistance but also promotes cell apoptosis. Further mechanistic research showed that LINC00261 sponged miR-545-3p which was negatively correlated with the expression of LINC00261. In addition, functional experiments revealed that upregulation of miR-766-5p promoted proliferation and enhanced DDP resistance. Subsequently, MT1M was testified to be the downstream target gene of miR-545-3p. Rescue experiments revealed that overexpression of MT1M largely restores miR-545-3p mimics-mediated function on ESCC progression. Our results demonstrate that the LINC00261 suppressed the DDP resistance of ESCC through miR-545-3p/MT1M axis.

UI MeSH Term Description Entries

Related Publications

Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
December 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
May 2022, Journal of clinical laboratory analysis,
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
February 2024, Journal of chemotherapy (Florence, Italy),
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
January 2022, Anti-cancer drugs,
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
January 2022, Open medicine (Warsaw, Poland),
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
April 2021, Experimental and therapeutic medicine,
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
February 2021, Free radical biology & medicine,
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
April 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
March 2022, Digestive diseases and sciences,
Lijun Wang, and Xiaojun Wang, and Pengwei Yan, and Yatian Liu, and Xuesong Jiang
January 2022, Human & experimental toxicology,
Copied contents to your clipboard!